TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05805670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga and Mindfulness
Description: Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to and 1 post-operative visit (24 hours after surgery)~The 5 sessions will be carried out 1 session/week from inclusion to the day before surgery
Study: NCT06316713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One MORE (Spanish Adaptation)
Description: One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into two, 1-hour segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Participants will also be guided through a mindful pain management practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The second segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, as well as learning to focus on increasing the positive emotions that can attenuate pain with mindful savoring.
Study: NCT05068960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Addition of liposomal bupivacaine to the interscalene block for extended pain control following total shoulder arthroplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Interscalene block with bupivacaine for pain control following total shoulder arthroplasty
Study: NCT04996667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled nitric oxide (iNO)
Description: Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled nitric oxide (iNO)
Description: Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes.
Study: NCT05647460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional plates
Description: mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
Study: NCT04670796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX02
Description: subject receive one dose of HLX02

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Trastuzumab (Herceptin®)
Description: subject receive one dose of EU-sourced Trastuzumab (Herceptin®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Trastuzumab (Herceptin®)
Description: subject receive one dose of US-licensed Trastuzumab (Herceptin®)
Study: NCT05604261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole sodium 40 mg
Description: Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole sodium 60 mg
Description: Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Study: NCT05068960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Interscalene block with bupivacaine for pain control following total shoulder arthroplasty
Study: NCT05604261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole sodium 20 mg
Description: Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Study: NCT06191276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP@Home Intervention
Description: STEP@Home is a multi-component exercise program designed for prefrail older adults that incorporates active strategies to promote long-term engagement. The optimal level of training is 45-60 minutes of exercise three times per week for at least 20 weeks. For prefrailty management, emphasis is placed on balancing and resistance training (around 15-20 min each) to improve muscle strength and gross mobility and prevent falls. Aerobic and flexibility exercises (10 min each) are also included to improve fitness and walking pace. Sixteen training tasks, including but not limited to those recommended by Vivifrail, for each exercise component (namely, resistance, balance, flexibility and aerobic training) will be adopted. A training manual with step-by-step illustrations of each task in pictures and text will be provided to the subjects, together with a set of simple, easy-to-access equipment (water bottle, elastic band and weight-bearing belt) to support task fulfilment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training.
Study: NCT06345768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: It is a ball 5-6 cm in size and not too hard. It will be given to both hands of the patients and they will be asked to count from 1 to 5. This application will be repeated for 15 minutes.
Study: NCT05000983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PluroGel
Description: A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressing
Description: Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
Study: NCT06417671

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotics supplementation
Description: The participants will consume one capsule per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: The participants will consume one capsule per day.
Study: NCT06278454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT6008 Injection + Systematic chemotherapy
Description: -Systematic chemotherapy The chemotherapy regimen is selected by the investigators at the consideration of participants' conditions, with either GN or (m)FOLFIRINOX.~GN: gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, every 21 days (3 weeks/cycle).~FOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 and fluorouracil 400 mg/m\^2 given as a bolus followed by 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~mFOLFIRINOX: oxaliplatin 85 mg/m\^2, irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2, and fluorouracil 2400 mg/m\^2 given as a 46-hour continuous infusion, every 2 weeks (4 weeks/cycle).~-NRT6008 injection administration: NRT6008 injection is implanted into pancreatic tumor via endoscopic ultrasound (EUS)-guided fine-needle injection, at the instruction of the investigator. The dose of NRT6008 injection is determined by tumor volume and estimated tumor average absorbed dose.
Study: NCT05685576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezotomed ridge splitting and osseodensification
Description: Ridge expansion using piezotomed ridge splitting and osseodensification
Study: NCT05038033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Description: The IPT group sessions follow three phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbating disinhibited eating and anxiety symptoms. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors and warning signs for excessive weight gain, such as eating in response to negative affect as opposed to hunger, or feeling a sense of loss-of-control while eating. IPT focuses on psychoeducation and general skill-building that can be applied to different relationships within the framework of four interpersonal problem areas: interpersonal role disputes, role transitions, interpersonal deficits, and grief.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Theory (CBT)
Description: The CBT program will be derived from Coping Cat, a manualized intervention for children and adolescents with elevated symptoms of anxiety. The group intervention builds skills for managing anxiety, in general, but with a focus on how anxiety prompts disinhibited eating, including attention to and restructuring of negative cognitions that perpetuate anxiety and behavioral exposure, rather than avoidance, of anxiety-provoking situations.
Study: NCT05905341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07224826
Description: Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07224826
Description: Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07224826
Description: Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07224826
Description: Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07224826
Description: Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07224826
Description: Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07224826
Description: Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
Study: NCT05834374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contextual variation
Description: The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum affordances
Description: The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
Study: NCT05905341

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
Study: NCT05636371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Communication
Description: Written patient care updates provided to families of ICU patients each day
Study: NCT05545579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circuit trainng
Description: Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes. The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trunk stabilization techniques
Description: The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
Study: NCT04972253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Oral, dosage per protocol
Study: NCT05820035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter
Description: All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
Study: NCT04838496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI Protocol
Description: FOLFOXIRI consists of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil and is administered every 2 weeks:~Dosing:~* Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA, followed by:~* Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV~* Day 3-14: rest days.~Both regimen are initially administered for four cycles. In case of responsive or stable disease, a 5th and 6th cycle of FOLFOXIRI will be administered.~In case of unacceptable toxicity, the aforementioned dosages can be reduced or one or more chemotherapeutical agents can be omitted at discretion of the medical oncologist and will be noted in the patient's medical file. At discretion of the medical oncologist, a start dosage of 75% of the advised dosage could be considered in patients above 70 years of age.
Study: NCT06044883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of Botulinum neurotoxin (BoNT)
Description: Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum, an anaerobic ,gram-positive bacterium. Poisoning with BoNT can cause botulism, resulting in generalized paralysis, respiratory failure, and death .There are seven serotypes of BoNT: A, B, C1, D, E, F, and G. BoNT-A is the most commonly used serotype for medical purposes.~Since its first use in 1977 for the treatment of strabismus in children, BoNT-A has since been used in aesthetic medicine and for the treatment of a number of disorders associated with overactive striated muscles, such as strabismus, esotropia, exotropia , focal dystonia, spasticity, and movement disorders.~BoNT-A has also been used in the management of some smooth-muscle disorders, such as achalasia, oesophageal spasm , ptyalism, hyperhidrosis, and intrinsic rhinitis, blepharospasm, muscle spasms and spasticity, axillary hyperhidrosis, and neurogenic detrusor muscle overactivity of the urinary bladder.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Penile duplex and shear wave elastosonography (SWE).
Description: Penile duplex study using intracavernosal injection of prostaglandin E1 (PGE1) before and after Botox injection (in the follow-up visit in the 6th week after Botox injection). Penile cavernosal arteries diameters and colored waves will be assessed. Shear wave elastosonography will be conducted comparing the stiffness of penile tissues before and after Botox injection
Study: NCT06544889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen SPF 70
Description: Participants will topically apply sunscreen SPF 70
Study: NCT04710394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smell Training
Description: Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smell Training
Description: Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smell Training
Description: Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
Study: NCT06018610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: In addition to conventional rehabilitation, relaxation exercises and classical massage of the sole of the foot will be applied to the study group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional rehabilitation will be applied to the control group.
Study: NCT06483165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BE FAST Educational video
Description: A 1-minute educational video format using BE FAST. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: F.A.S.T. Educational Video
Description: A 1-minute educational video format using F.A.S.T. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
Study: NCT04710394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smell Training
Description: Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
Study: NCT04750161

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be given to participants. It is purely observational.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be given to participants. It is purely observational.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be given to participants. It is purely observational.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be given to participants. It is purely observational.
Study: NCT05291533

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality (VR) Mindfulness Program
Description: The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
Study: NCT04971928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be administered